Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cell and gene therapies - Athenex/Baylor College of Medicine

Next Previous
Search
Drug Profile

Research programme: cell and gene therapies - Athenex/Baylor College of Medicine

Alternative Names: CAR-modified NKT cell therapy; CMD 504; CMD 601; Off-the-shelf allogeneic cell therapy; Off-the-shelf allogeneic NKT

Latest Information Update: 17 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Athenex
  • Class Gene therapies; NKT cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 12 Sep 2023 Discontinued - Preclinical for Haematological malignancies in USA (Parenteral)
  • 12 Sep 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
  • 28 Jun 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top